

## **Helix BioMedix Appoints Jack Clifford to Board of Directors; Moves Small Molecule Pharmaceutical Program Forward**

*Sep 17, 2007 - Bothell, Washington*

Helix BioMedix, Inc., (OTCBB: HXBM - News), a biopharmaceutical company with an extensive library of diverse bioactive peptides, today announced the appointment of Jack Clifford to its board of directors, and its progress in the achievement of strategic milestones.

"Jack brings to Helix BioMedix extensive experience and industry relationships at an important point in the company's development," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix, regarding the appointment of Mr. Clifford. "His past expertise with negotiating license agreements for both consumer and pharmaceutical peptide applications with companies such as Neutrogena, Merck and C.R. Bard, will prove invaluable as we continue our efforts to further commercialize our peptides and develop our pharmaceutical program."

Clifford recently served as Chairman, President and Chief Executive Officer of Procyte Corporation, a developer of skin, hair and wound care products for dermatological and surgical applications, which was acquired by Photomedex in 2005 where he subsequently served as Executive Vice President of Dermatology. Prior to Procyte, Clifford held a number of senior executive management positions, which included: President of Orthofix, Inc. following its acquisition of American Medical Electronics where he was President and Chief Executive Officer; Division Vice President of American Cyanamid; President and Chief Operating Officer of Lukens Medical Corporation; and sales, marketing, and product management positions with Iolab Corporation and Ethicon, Inc., both Johnson and Johnson subsidiaries. In addition to his executive positions, Clifford has served on the board of directors at Emerald Pharmaceutical, a contract manufacturer serving biotech and pharmaceutical companies, and NextDerm, Inc., a developer of pharmaceutical products for dermatological applications. He holds a Bachelor of Science in Economics from Villanova University and a Masters of Business Administration in finance from Drexel University.

"Helix BioMedix is well positioned to establish itself as a leader in the development and commercialization of bioactive peptides for both pharmaceutical and non-pharmaceutical uses," stated Mr. Clifford. "I look forward to working with Mr. Beatty, the other members of the company's management team, and my fellow board members and believe my past experiences and relationships will add significant value as the company expands its business."

Helix BioMedix also announced that beginning with the fourth quarter, it plans to focus substantial energies on the development of its small molecule pharmaceutical program. "We are in early discussions with both potential pharmaceutical partners and investment partners to determine the best path forward for this very exciting program," stated Beatty.

"Our previously-announced milestone for the end of 2007 is to enter negotiations for the out-licensing of certain rights to our topical anti-infective platform. We have made good progress on this goal and are currently in early discussions with a number of pharmaceutical and dermatology-based companies. Due to the breadth of application of our novel small molecule peptide technology we also have the opportunity to create significant value through in-house development of these molecules, and therefore are also exploring

a number of funding opportunities. The value proposition for novel molecules exhibiting demonstrable antibacterial and antifungal activities in independently run animal infection models is significant. We believe these programs will enable the company to expand from its existing presence in the dermatology market into the pharmaceutical segment, creating long term value," Mr. Beatty continued.

To move forward as the company expands its focus beyond non-prescription skincare and dermatology-based products, it will be creating a new VP position to be filled by a person with significant experience in the clinical development of dermatology and anti-infective therapeutics.

"We have also moved the consumer products side of our company significantly forward, as evidenced by the two strategic marketing partnerships we have established in the last 12 months and the completion of the first phase of development for our planned 2008 rollout of a topical anti-aging product. As a result, our peptides are now featured in products that are sold in such stores as Walgreens, CVS, Rite Aid, Nordstrom, Whole Foods, Longs, and Wild Oats. With the anticipated rollout of our acne product, PAC Perfect(TM), through our joint venture with DermaVentures, we will have accomplished all three of our 2007 strategic goals involving consumer products."

#### **About Helix BioMedix, Inc.**

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically applied products that offer the health, beauty and safety benefits of advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptide technology.

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners.

More information about the company and its proprietary peptides may be found on the company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).

#### **Forward-Looking Statements**

This press release contains forward-looking statements regarding Helix BioMedix, Inc. (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable

peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the Helix BioMedix, Inc. website or at [www.sec.gov](http://www.sec.gov). Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. Helix BioMedix, Inc. undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

**Contacts:**

**Shelton Group Investor Relations Contact:**

Investor Contact:

Ryan Bright

Marketing Manager, Actives

972-239-5119 X 159

[rbright@sheltongroup.com](mailto:rbright@sheltongroup.com)

or

**Helix BioMedix Contact:**

R. Stephen Beatty

President and CEO

425-402-8400

[sbeatty@helixbiomedix.com](mailto:sbeatty@helixbiomedix.com)

Source: Helix BioMedix, Inc.